Loading

An Innovative Approach to Treatment

State-of-the-art therapy for all hematological disorders

State-of-the-art therapy for all hematological disorders

Daycare BMT services to eligible patients of multiple myeloma

Daycare BMT services to eligible patients of multiple myeloma

State-of-the-art BMT rooms with HEPA filters as per international standards

State-of-the-art BMT rooms with HEPA filters as per international standards

Haploidentical BMT Services including T-cell Depleted and Immunotherapy Services

Haploidentical BMT Services including T-cell Depleted and Immunotherapy Services

We Specialise in the Treatment of

Hemophilia

Primary Immunodeficiency Disorders

Wilms’ Tumour

Neuroblastoma

Soft Tissue Sarcoma

Retinoblastoma

Paediatric Solid Tumors

Hematological Malignancies like Leukemia, Lymphoma, Myeloma

Thrombotic Disorders

Hematology

Thrombotic Microangiopathy

Aplastic Anemia

Autoimmune Hemolytic Anemia

Sickle Cell Anemia

Thalassemia

BMT Care

Paediatric Oncology

Bone Marrow Transplant Experts

Dr_-Mahesh-Rajashekaraih.jpg

Dr. Mahesh Rajashekaraiah

Head of Haematology and Bone Marrow Transplant Department

Dr_-Sunil-Udgire.jpg

Dr. Sunil Udgire

Consultant Haematologist, Paediatric Oncologist and BMT Physician

Bone Marrow Transplant FAQs

The types of bone marrow transplant are:

1) Autologous BMT - Where a patient’s own stem cells are given as rescue therapy following high dose chemotherapy as in multiple myeloma, refractive lymph, and certain paediatric solid tumours.

2) Allogeneic BMT - Where stem cells of the donor are given to the patient after conditioning chemotherapy to treat the underlying condition. Types of Allogeneic BMT further are:

  • Matched family donor BMT - Full HLA match within the family, especially siblings
  • Matched unrelated donor BMT - HLA matched donors outside the family from stem cell registry
  • Haploidentical BMT - Half matched within the donor’s family, there are two types: Post-transplant Cyclophosphamide (PTCy) and T-cell depleted BMT

The definitive estimation of success of treatment depends on the particular disease, risk stratification, etc. Thalassemia (low risk) can be cured in 80-90% cases and high risk leukaemia has a success rate of 50% to 60%.

Book An
Appointment